Breakthrough Neurostimulation Technology Granted Patent for Alzheimer’s Treatment: Nexalin Unveils Potential Future of Mental Health Care

Nexalin Technology Inc. announced on Thursday that they have been awarded U.S. Patent No 12,011,591 by the United States Patent and Trademark Office for their noninvasive Deep Intracranial Frequency Stimulation (DIFS) medical device. This device is designed to treat Alzheimer’s and other dementia-related brain diseases. The patent was granted on June 18 and is related to the company’s Gen-2 and Gen-3 brain stimulation medical device.

The growing global market for dementia treatment is estimated to be over $18 billion and projected to reach over $28 billion by 2030. With the increasing number of people living with dementia and the significant investments in research and development, innovative treatments like Nexalin’s neurostimulation device are essential. The company’s published clinical studies support the clinical benefits of their device for treating various neurological diseases, from depression to migraines, anxiety, insomnia, addiction, and PTSD.

Nexalin believes that their DIFS technology has the potential to revolutionize the standard of care for mental health disorders such as Alzheimer’s and dementia. The Gen-2 and Gen-3 stimulation techniques use strategically positioned electrodes on the patient’s cranium to provide deep stimulation to brain regions associated with mental health conditions. As of Thursday morning, NXL shares were up 36.5% at $1.42 during the premarket session.